Compare DLTR & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLTR | TEVA |
|---|---|---|
| Founded | 1986 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.8B | 30.2B |
| IPO Year | 1995 | N/A |
| Metric | DLTR | TEVA |
|---|---|---|
| Price | $122.34 | $28.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 8 |
| Target Price | ★ $113.29 | $27.00 |
| AVG Volume (30 Days) | 3.7M | ★ 11.4M |
| Earning Date | 12-03-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.62 |
| Revenue | ★ $18,960,900,000.00 | $16,776,000,000.00 |
| Revenue This Year | $12.76 | $4.74 |
| Revenue Next Year | $5.97 | $0.48 |
| P/E Ratio | ★ $23.07 | $46.12 |
| Revenue Growth | ★ 156.37 | 0.02 |
| 52 Week Low | $61.80 | $12.47 |
| 52 Week High | $125.79 | $28.68 |
| Indicator | DLTR | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 74.53 | 80.93 |
| Support Level | $107.44 | $24.01 |
| Resistance Level | $111.95 | $26.96 |
| Average True Range (ATR) | 4.41 | 0.68 |
| MACD | 1.53 | 0.19 |
| Stochastic Oscillator | 87.40 | 94.65 |
Dollar Tree operates discount stores across the United States and Canada, with over 8,800 shops under its namesake banner. About 50% of Dollar Tree's sales in fiscal 2024 were consumables (including food, health and beauty, and cleaning products), around 45% variety items (including toys and homewares), and 5% seasonal items. Dollar Tree sells most of its merchandise at the $1.25 price point and positions its stores in well-populated suburban markets. The retailer has agreed to sell Family Dollar (with about 7,000 stores) to private equity investors for $1 billion.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.